Cyxone, a biotech company specializing in autoimmune diseases, in collaboration with its CDMO partner, has streamlined part of the manufacturing process for its drug candidate Rabeximod, which is under development for the treatment of rheumatoid arthritis (RA).
STOCKHOLM, Nov. 10, 2020 /PRNewswire/ -- Cyxone (publ.) announced today that the company has filed for an extended patent protection of Rabeximod with the European Patent Office (EPO), that will be extended to other territories in due course. An approval of the application will strengthen the company's intellectual property portfolio and generate a longer market exclusivity for Rabeximod.
STOCKHOLM, Sept. 24, 2020 /PRNewswire/ -- Cyxone AB (publ), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, announces today that it has initiated a process to optimize the development plan for Rabeximod. This initiative is based on valuable input from the company's new senior medical advisors, updated market intelligence and the opportunity to prolong market exclusivity through newly filed patent applications. In parallel, the company is preparing a phase 2 clinical study of Rabeximod in Covid-19 patients, with a potential initiation already in the fourth quarter of 2020.
Cyxone (publ), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, announces today that it plans to initiate a phase 2 clinical trial with Rabeximod in Covid-19 patients. The treatment is intended to reduce the risk of developing severe respiratory symptoms caused by virus-related overactivation of the immune system.
STOCKHOLM, July 6, 2020 /PRNewswire/ -- Cyxone (publ), a Swedish biotech in autoimmune diseases, announces today that the company has engaged Dr Maarten Kraan as Senior Scientific Advisor for the company's project for Rabeximod in rheumatoid arthritis (RA).